“Obtaining U.S. FDA approval for our drug platform remains a priority for NurExone and we intend to continue working towards expediting this process by submitting a Pre-IND meeting request,” said Dr. Lior Shaltiel, CEO of NurExone. “In addition to pursuing our regulatory objective, we are advancing other areas of our business, including securing more international collaborations with biotechnology companies and completing more key scientific initiatives. We have also strengthened our balance sheet by settling EnerSpar Corp.’s debts (the predecessor company to NurExone) that were incurred prior to our go-public listing.”